Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
19 Leser
Artikel bewerten:
(0)

Stryker Hip Lawsuit News: Device Maker Takes $161 Million Second Quarter Charge Relating to Rejuvenate and ABG II Hip Stem Recall, Bernstein Liebhard LLP Reports

NEW YORK, July 21, 2014 /PRNewswire/ -- The Stryker hip recall (http://www.strykerhiprecallclaims.com/) for Rejuvenate and ABG II Modular-Neck Hip Stems continues to impact the company's earnings, Bernstein Liebhard LLP reports. During a conference call held on July 17, 2014 to discuss second quarter results, Stryker's Chief Financial Officer reported that charges related to the Rejuvenate and ABG II recall increased by $160 million during the period. The company also noted that charges associated with the 2012 recall may increase or decrease over time, and that no insurance proceeds that could potentially be available to cover some of those costs were included in the second-quarter figures.

Bernstein Liebhard LLP.

"Thousands of Stryker hip lawsuits have been filed in U.S. courts since the announcement of the Rejuvenate and ABG II recall. It is not at all surprising that the company's costs related to this matter continue to grow," says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is offering free Stryker hip lawsuit reviews to individuals who allegedly suffered serious complications related to the Rejuvenate and ABG II hip stem recall.

Stryker Hip Recall

The U.S. Food & Drug Administration announced the recall of Rejuvenate and ABG II hip stems in July 2012, after the metal hip components were found to be vulnerable to fretting and corrosion at the modular-neck junction. According to Stryker, the recalled hip stems may cause recipients to experience pain, swelling, and adverse local tissue reactions. Stryker has advised those fitted with Rejuvenate or ABG II hip stems to undergo metal ion blood testing and imaging studies to ensure the components are functioning properly, even if they have not experienced any symptoms that would indicate otherwise.

According to court documents, more than 3,700 Stryker hip lawsuits have been filed in courts around the country since the Rejuvenate and ABG II hip stems were pulled from the market in 2012. These include at least 2,051 cases that are pending in a multicounty litigation now underway in New Jersey's Bergen County Superior Court, where Bernstein Liebhard LLP is actively filing claims. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296)

An additional 1,692 product liability claims relating to the Stryker hip recall have been filed in a federal multidistrict litigation currently underway in U.S. District Court, District of Minnesota. (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, MDL No. 2441)

All of these Stryker hip lawsuits similarly allege that recipients of the Rejuvenate and ABG II components suffered metallosis, adverse local tissue reactions, necrosis, and other serious complications due to the propensity of the components to fret and corrode. The lawsuits further claim that many of these individuals continue to suffer pain and disability, despite having undergone surgery to replace their failing hip implant.

Individuals who were allegedly injured by Rejuvenate and ABG II hip stems may be entitled to compensation for their medical bills, lost wages, pain and suffering, and other damages. To learn more about filing a Stryker hip lawsuit, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling (888) 340-4807.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.strykerhiprecallclaims.com/
https://plus.google.com/115936073311125306742?rel=author

Logo - http://photos.prnewswire.com/prnh/20120202/MM47134LOGO

SOURCE Bernstein Liebhard LLP

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.